These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 36163066)

  • 1. Gasdermin B over-expression modulates HER2-targeted therapy resistance by inducing protective autophagy through Rab7 activation.
    Gámez-Chiachio M; Molina-Crespo Á; Ramos-Nebot C; Martinez-Val J; Martinez L; Gassner K; Llobet FJ; Soriano M; Hernandez A; Cordani M; Bernadó-Morales C; Diaz E; Rojo-Sebastian A; Triviño JC; Sanchez L; Rodríguez-Barrueco R; Arribas J; Llobet-Navás D; Sarrió D; Moreno-Bueno G
    J Exp Clin Cancer Res; 2022 Sep; 41(1):285. PubMed ID: 36163066
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intracellular Delivery of an Antibody Targeting Gasdermin-B Reduces HER2 Breast Cancer Aggressiveness.
    Molina-Crespo Á; Cadete A; Sarrio D; Gámez-Chiachio M; Martinez L; Chao K; Olivera A; Gonella A; Díaz E; Palacios J; Dhal PK; Besev M; Rodríguez-Serrano M; García Bermejo ML; Triviño JC; Cano A; García-Fuentes M; Herzberg O; Torres D; Alonso MJ; Moreno-Bueno G
    Clin Cancer Res; 2019 Aug; 25(15):4846-4858. PubMed ID: 31064780
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gasdermin B expression predicts poor clinical outcome in HER2-positive breast cancer.
    Hergueta-Redondo M; Sarrio D; Molina-Crespo Á; Vicario R; Bernadó-Morales C; Martínez L; Rojo-Sebastián A; Serra-Musach J; Mota A; Martínez-Ramírez Á; Castilla MÁ; González-Martin A; Pernas S; Cano A; Cortes J; Nuciforo PG; Peg V; Palacios J; Pujana MÁ; Arribas J; Moreno-Bueno G
    Oncotarget; 2016 Aug; 7(35):56295-56308. PubMed ID: 27462779
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HO-1 drives autophagy as a mechanism of resistance against HER2-targeted therapies.
    Tracey N; Creedon H; Kemp AJ; Culley J; Muir M; Klinowska T; Brunton VG
    Breast Cancer Res Treat; 2020 Feb; 179(3):543-555. PubMed ID: 31705351
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gasdermin-B promotes invasion and metastasis in breast cancer cells.
    Hergueta-Redondo M; Sarrió D; Molina-Crespo Á; Megias D; Mota A; Rojo-Sebastian A; García-Sanz P; Morales S; Abril S; Cano A; Peinado H; Moreno-Bueno G
    PLoS One; 2014; 9(3):e90099. PubMed ID: 24675552
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulation of cell survival by HUNK mediates breast cancer resistance to HER2 inhibitors.
    Yeh ES; Abt MA; Hill EG
    Breast Cancer Res Treat; 2015 Jan; 149(1):91-8. PubMed ID: 25515931
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Autophagy-related gene 12 (ATG12) is a novel determinant of primary resistance to HER2-targeted therapies: utility of transcriptome analysis of the autophagy interactome to guide breast cancer treatment.
    Cufí S; Vazquez-Martin A; Oliveras-Ferraros C; Corominas-Faja B; Urruticoechea A; Martin-Castillo B; Menendez JA
    Oncotarget; 2012 Dec; 3(12):1600-14. PubMed ID: 23307622
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A class I histone deacetylase inhibitor, entinostat, enhances lapatinib efficacy in HER2-overexpressing breast cancer cells through FOXO3-mediated Bim1 expression.
    Lee J; Bartholomeusz C; Mansour O; Humphries J; Hortobagyi GN; Ordentlich P; Ueno NT
    Breast Cancer Res Treat; 2014 Jul; 146(2):259-72. PubMed ID: 24916181
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Her2-Targeted Therapy Induces Autophagy in Esophageal Adenocarcinoma Cells.
    Janser FA; Adams O; Bütler V; Schläfli AM; Dislich B; Seiler CA; Kröll D; Langer R; Tschan MP
    Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30297650
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phosphoproteomic analysis reveals PAK2 as a therapeutic target for lapatinib resistance in HER2-positive breast cancer cells.
    Chang Y; Park KH; Lee JE; Han KC
    Biochem Biophys Res Commun; 2018 Oct; 505(1):187-193. PubMed ID: 30243723
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gasdermin-B Pro-Tumor Function in Novel Knock-in Mouse Models Depends on the
    Sarrio D; Rojo-Sebastián A; Teijo A; Pérez-López M; Díaz-Martín E; Martínez L; Morales S; García-Sanz P; Palacios J; Moreno-Bueno G
    Front Cell Dev Biol; 2022; 10():813929. PubMed ID: 35281099
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor-Associated Fibroblasts Promote HER2-Targeted Therapy Resistance through FGFR2 Activation.
    Fernández-Nogueira P; Mancino M; Fuster G; López-Plana A; Jauregui P; Almendro V; Enreig E; Menéndez S; Rojo F; Noguera-Castells A; Bill A; Gaither LA; Serrano L; Recalde-Percaz L; Moragas N; Alonso R; Ametller E; Rovira A; Lluch A; Albanell J; Gascon P; Bragado P
    Clin Cancer Res; 2020 Mar; 26(6):1432-1448. PubMed ID: 31699826
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RANK signaling increases after anti-HER2 therapy contributing to the emergence of resistance in HER2-positive breast cancer.
    Sanz-Moreno A; Palomeras S; Pedersen K; Morancho B; Pascual T; Galván P; Benítez S; Gomez-Miragaya J; Ciscar M; Jimenez M; Pernas S; Petit A; Soler-Monsó MT; Viñas G; Alsaleem M; Rakha EA; Green AR; Santamaria PG; Mulder C; Lemeer S; Arribas J; Prat A; Puig T; Gonzalez-Suarez E
    Breast Cancer Res; 2021 Mar; 23(1):42. PubMed ID: 33785053
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protective autophagy promotes the resistance of HER2-positive breast cancer cells to lapatinib.
    Chen S; Zhu X; Qiao H; Ye M; Lai X; Yu S; Ding L; Wen A; Zhang J
    Tumour Biol; 2016 Feb; 37(2):2321-31. PubMed ID: 26369543
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PTK6 inhibition promotes apoptosis of Lapatinib-resistant Her2(+) breast cancer cells by inducing Bim.
    Park SH; Ito K; Olcott W; Katsyv I; Halstead-Nussloch G; Irie HY
    Breast Cancer Res; 2015 Jun; 17(1):86. PubMed ID: 26084280
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting the EphB4 receptor tyrosine kinase sensitizes HER2-positive breast cancer cells to Lapatinib.
    Ding J; Yao Y; Huang G; Wang X; Yi J; Zhang N; Liu C; Wang K; Zhang Y; Wang M; Liu P; Ye M; Li M; Cheng H
    Cancer Lett; 2020 Apr; 475():53-64. PubMed ID: 32006616
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NF-κB activation-induced anti-apoptosis renders HER2-positive cells drug resistant and accelerates tumor growth.
    Bailey ST; Miron PL; Choi YJ; Kochupurakkal B; Maulik G; Rodig SJ; Tian R; Foley KM; Bowman T; Miron A; Brown M; Iglehart JD; Debajit KB
    Mol Cancer Res; 2014 Mar; 12(3):408-420. PubMed ID: 24319068
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination treatment with a PI3K/Akt/mTOR pathway inhibitor overcomes resistance to anti-HER2 therapy in PIK3CA-mutant HER2-positive breast cancer cells.
    Fujimoto Y; Morita TY; Ohashi A; Haeno H; Hakozaki Y; Fujii M; Kashima Y; Kobayashi SS; Mukohara T
    Sci Rep; 2020 Dec; 10(1):21762. PubMed ID: 33303839
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of HER2 Increases JAGGED1-dependent Breast Cancer Stem Cells: Role for Membrane JAGGED1.
    Shah D; Wyatt D; Baker AT; Simms P; Peiffer DS; Fernandez M; Rakha E; Green A; Filipovic A; Miele L; Osipo C
    Clin Cancer Res; 2018 Sep; 24(18):4566-4578. PubMed ID: 29895705
    [No Abstract]   [Full Text] [Related]  

  • 20. Cleavage of the extracellular domain of junctional adhesion molecule-A is associated with resistance to anti-HER2 therapies in breast cancer settings.
    Leech AO; Vellanki SH; Rutherford EJ; Keogh A; Jahns H; Hudson L; O'Donovan N; Sabri S; Abdulkarim B; Sheehan KM; Kay EW; Young LS; Hill ADK; Smith YE; Hopkins AM
    Breast Cancer Res; 2018 Nov; 20(1):140. PubMed ID: 30458861
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.